Oligodendrocyte Progenitor Cell Culture From Human Brain

Department of Medical Services Ministry of Public Health of Thailand5 enrolled

Overview

Recent developments in the understanding of stem- and progenitor cell differentiation raises hopes that brain damage in chronic neurological diseases may become repaired by systemic or focal transplantation of such cells. Clinical trials of stem- or progenitor cell transplantation in multiple sclerosis are currently premature. The researchers developed a protocol for human oligodendrocyte progenitor cell culture from human brain for the treatment of demyelinating disease.

Oligodendrocyte progenitor cell line were cultures and will be transplanted into the patient with Multiple sclerosis.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Demyelinating Diseases

Interventions

Oligodendrocyte progenitor cell culture/craniotomyPROCEDURE

Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply

Eligibility

Sex: ALLMin age: 20 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female 20-65 years of age * Informed consent * Has elective craniotomy surgery Exclusion Criteria: * HIV, hepatitis, and other central nervous system (CNS) infections * Dementia, Alzheimer disease, and neurodegenerative disease

Locations (1)

Assistant Professor Subsai Kongsaengdao

Bangkok, Thailand

Outcomes

Primary Outcomes

Number of oligodendrocyte progenitor cell differentiation

Time frame: one month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.